The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: A 3-year, randomized, multicenter, double-blind, placebo-controlled study

Clinical Therapeutics

Volumn 30, Issue 3, 2008, Pages 482-498

  Esnault, Vincent L M ^a   Brown, Edwina A ^b   Apetrei, Eduard ^c   Bagon, Jacques ^d   Calvo, Carlos ^e   DeChatel, Rudolf ^f   Holdaas, Hallvard ^g   Krcmery, Silvester ^h   Kobalava, Zhanna ⁱ  

^a PASTEUR HOSPITAL   (France)

^b CHARING CROSS HOSPITAL   (United Kingdom)

^c FUNDENI CLINICAL INSTITUTE   (Romania)

^d St Jean Hosp   (Belgium)

^e University Hospital of Santiago de Compostela   (Spain)

^f SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

^h Bratislava   (Slovakia)

ⁱ PEOPLES FRIENDSHIP UNIVERSITY OF RUSSIA   (Russian Federation)

Author keywords

angiotensin converting enzyme inhibitors; calcium channel blockers; chronic renal failure; diuretics; glomerular filtration rate; proteinuria; randomized placebo controlled trial

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; EDETATE CHROMIUM CR 51; ENALAPRIL; FUROSEMIDE; METHYLDOPA; PLACEBO; PRAZOSIN; RILMENIDINE; TORASEMIDE; VASODILATOR AGENT;

ABDOMINAL PAIN; ACIDOSIS; ADD ON THERAPY; ADULT; AGED; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE CLEARANCE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEADACHE; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERIPHERAL EDEMA; PHARYNGITIS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; THROAT IRRITATION; TREATMENT DURATION; URINARY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; COHORT STUDIES; CREATININE; DOUBLE-BLIND METHOD; ENALAPRIL; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; KIDNEY; KIDNEY DISEASES; MALE; MIDDLE AGED; PLACEBOS; TREATMENT OUTCOME;

EID: 41649101421     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.03.006     Document Type: Article

References (43)

1. Ruggenenti P., Schieppati A., and Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet 357 (2001) 1601-1608
2. Jafar T., Stark P., Schmid C., et al., for the AIPRD Study Group. Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensinconverting enzyme inhibition: A patient-level metaanalysis. Ann Intern Med 139 (2003) 244-252
3. Casas J., Chua W., Loukogeorgakis S., et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: Systematic review and meta-analysis. Lancet 366 (2005) 2026-2033
4. Remuzzi G., Perico N., Macia M., and Ruggenenti P. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl 99 (2005) S57-S65
5. Hayashi K., Wakino S., Sugano N., et al. Ca2+ channel subtypes and pharmacology in the kidney. Circ Res 100 (2007) 342-353
6. Weidmann P., Boehlen L., de Courten M., and Ferrari P. Antihypertensive therapy in diabetic patients. J Hum Hypertens 6 Suppl 2 (1992) S23-S36
7. Lewis E., Hunsicker L., Bain R., Rohde R., and for the Collaborative Study Group. The effect of angiotensinconverting-enzyme inhibition on diabetic nephropathy. [published correction appears in N Engl J Med 1993;330:152]. N Engl J Med 329 (1993) 1456-1462
8. Maschio G., Alberti D., Janin G., et al., for the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Effect of the angiotensin-convertingenzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334 (1996) 939-945
9. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebocontrolled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349 (1997) 1857-1863
10. Ruggenenti P., Perna A., Gherardi G., et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354 (1999) 359-364
11. Parving H., Lehnert H., Bröchner-Mortensen J., et al., for the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345 (2001) 870-878
12. Brenner B., Cooper M., de Zeeuw D., et al., for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
13. Lewis E., Hunsicker L., Clarke W., et al., for the Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
14. Hou F., Zhang X., Zhang G., et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 354 (2006) 131-140
15. Zucchelli P., Zuccalà A., Borghi M., et al. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 42 (1992) 452-458
16. Marin R., Ruilope L., Aljama P., et al., for the Investigators of the ESPIRAL Study (Efecto del tratamiento antihipertensivo Sobre la Progresión de la Insuficiencia RenAL en pacientes no diabéticos). A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease. J Hypertens 19 (2001) 1871-1876
17. Herlitz H., Harris K., Risler T., et al. The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: The Nephros Study. Nephrol Dial Transplant 16 (2001) 2158-2165
18. Agodoa L., Appel L., Bakris G., et al., for the African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA 285 (2001) 2719-2728
19. Wright Jr. J., Bakris G., Greene T., et al., for the African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. [published correction appears in JAMA 2006;295:2726]. JAMA 288 (2002) 2421-2431
20. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [published corrections appear in JAMA 2003;289:178 and JAMA. 2004;291:2196]. JAMA 288 (2002) 2981-2997
21. Rahman M., Pressel S., Davis B., et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: A report from the Anti-hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 165 (2005) 936-946
22. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. [published correction appears in Arch Intern Med. 1998; 158:573]. Arch Intern Med 157 (1997) 2413-2446
23. Snedecor G., and Cochran W. Statistical Methods (1980), The Iowa State University Press, Ames, Iowa
24. Kalbfleisch J., and Prentice R. The Statistical Analysis of Failure Time Data (1980), John Wiley and Sons, New York, NY
25. Esnault V., Ekhlas A., Delcroix C., et al. Diuretic and enhanced sodium restriction results in improved anti-proteinuric response to RAS blocking agents. J Am Soc Nephrol 16 (2005) 474-481
26. Esnault V. Angiotensin-convertingenzyme inhibitors and diuretics for hypertension. N Engl J Med 349 (2003) 90-93
27. Ruggenenti P., Perna A., Remuzzi G., and for the GISEN Group Investigators. Retarding progression of chronic renal disease: The neglected issue of residual proteinuria. Kidney Int 63 (2003) 2254-2261
28. Jafar T., Schmid C., Landa M., et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. [published correction appears in Ann Intern Med. 2002;137:299]. Ann Intern Med 135 (2001) 73-87
29. Jafar T., Schmid C., and Levey A. Effect of angiotensin-converting enzyme inhibitors on progression of nondiabetic renal disease. Ann Intern Med 137 (2002) 298-299
30. Buter H., Hemmelder M., Navis G., et al. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 13 (1998) 1682-1685
31. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. [published corrections appear in J Hypertens 2003;21:2203-2204 and J Hypertens. 2004;22:435]. J Hypertens 21 (2003) 1011-1053
32. Esnault V. Renoprotective properties of angiotensin-converting enzyme inhibitors: Proofs and limits?. Nephron 85 (2000) 183-184
33. Dworkin L., Grosser M., Feiner H., et al. Renal vascular effects of antihypertensive therapy in uninephrectomized SHR. Kidney Int 35 (1989) 790-798
34. Benediktsson H., Chea R., Davidoff A., and Paul L. Antihypertensive drug treatment in chronic renal allograft rejection in the rat. Effect on structure and function. Transplantation 62 (1996) 1634-1642
35. Contreras G., Greene T., Agodoa L., et al., for the African American Study of Kidney Disease and Hypertension Study Group Investigators. Blood pressure control, drug therapy, and kidney disease. Hypertension 46 (2005) 44-50
36. Bakris G., Weir M., Shanifar S., et al., for the RENAAL Study Group. Effects of blood pressure level on progression of diabetic nephropathy: Results from the RENAAL study. Arch Intern Med 163 (2003) 1555-1565
37. Ruggenenti P., Perna A., Loriga G., et al., for the REIN-2 Study Group. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): Multicentre, randomised controlled trial. Lancet 365 (2005) 939-946
38. Bakris G., Weir M., Secic M., et al. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 65 (2004) 1991-2002
39. Preston R., Materson B., Reda D., et al., for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Proteinuria in mild to moderate hypertension: Results of the VA cooperative study of six antihypertensive agents and placebo. Clin Nephrol 47 (1997) 310-315
40. PROCOPA Study Group. Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease: A randomized double-blind trial. J Hypertens 20 (2002) 729-737
41. Ruggenenti P., Fassi A., Ilieva A., et al., for the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351 (2004) 1941-1951
42. Griffin K., Picken M., Bakris G., and Bidani A. Comparative effects of selective T- and L-type calcium channel blockers in the remnant kidney model. Hypertension 37 (2001) 1268-1272
43. Ma G., Allen T., Cooper M., and Cao Z. Calcium channel blockers, either amlodipine or mibefradil, ameliorate renal injury in experimental diabetes. Kidney Int 66 (2004) 1090-1098